Vir Biotechnology, GSK Terminate Collaboration on Flu
By Denny Jacob
Vir Biotechnology and GSK terminated their collaboration regarding the flu.
The clinical-stage immunology company and GSK collaborated to research, develop and commercialize Vir's monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus under an agreement established in May 2021.
Vir said the change reflects that it retains sole rights to continue advancing its investigational therapies for influenza independently or with other partners. The company added that it's actively pursuing external partnership opportunities for its next-generation influenza A and B antibodies and antibody drug conjugates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 22, 2024 16:57 ET (21:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization